BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 20458070)

  • 21. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
    Smach MA; Charfeddine B; Lammouchi T; Harrabi I; Ben Othman L; Dridi H; Bennamou S; Limem K
    Neurosci Lett; 2008 Aug; 440(2):145-9. PubMed ID: 18555606
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment.
    Stefani A; Martorana A; Bernardini S; Panella M; Mercati F; Orlacchio A; Pierantozzi M
    J Neurol Sci; 2006 Dec; 251(1-2):124-8. PubMed ID: 17097109
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample.
    Ibach B; Binder H; Dragon M; Poljansky S; Haen E; Schmitz E; Koch H; Putzhammer A; Kluenemann H; Wieland W; Hajak G
    Neurobiol Aging; 2006 Sep; 27(9):1202-11. PubMed ID: 16085339
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of cerebrospinal fluid tau/beta-amyloid(42) ratio as diagnostic markers for Alzheimer disease.
    Smach MA; Charfeddine B; Ben Othman L; Lammouchi T; Dridi H; Nafati S; Ltaief A; Bennamou S; Limem K
    Eur Neurol; 2009; 62(6):349-55. PubMed ID: 19786779
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated beta-amyloid peptides.
    Höglund K; Hansson O; Buchhave P; Zetterberg H; Lewczuk P; Londos E; Blennow K; Minthon L; Wiltfang J
    Neurodegener Dis; 2008; 5(5):268-76. PubMed ID: 18309230
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CSF biomarkers in Alzheimer's disease and controls: associations with APOE genotype are modified by age.
    Kester MI; Blankenstein MA; Bouwman FH; van Elk EJ; Scheltens P; van der Flier WM
    J Alzheimers Dis; 2009; 16(3):601-7. PubMed ID: 19276554
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan.
    Kanai M; Matsubara E; Isoe K; Urakami K; Nakashima K; Arai H; Sasaki H; Abe K; Iwatsubo T; Kosaka T; Watanabe M; Tomidokoro Y; Shizuka M; Mizushima K; Nakamura T; Igeta Y; Ikeda Y; Amari M; Kawarabayashi T; Ishiguro K; Harigaya Y; Wakabayashi K; Okamoto K; Hirai S; Shoji M
    Ann Neurol; 1998 Jul; 44(1):17-26. PubMed ID: 9667589
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects.
    Maccioni RB; Lavados M; Guillón M; Mujica C; Bosch R; Farías G; Fuentes P
    Neurobiol Aging; 2006 Feb; 27(2):237-44. PubMed ID: 16399209
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CSF biomarkers for Alzheimer's Disease: levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival.
    Wallin AK; Blennow K; Andreasen N; Minthon L
    Dement Geriatr Cogn Disord; 2006; 21(3):131-8. PubMed ID: 16391474
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Longitudinal changes of CSF biomarkers in memory clinic patients.
    Bouwman FH; van der Flier WM; Schoonenboom NS; van Elk EJ; Kok A; Rijmen F; Blankenstein MA; Scheltens P
    Neurology; 2007 Sep; 69(10):1006-11. PubMed ID: 17785669
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings.
    Seppälä TT; Nerg O; Koivisto AM; Rummukainen J; Puli L; Zetterberg H; Pyykkö OT; Helisalmi S; Alafuzoff I; Hiltunen M; Jääskeläinen JE; Rinne J; Soininen H; Leinonen V; Herukka SK
    Neurology; 2012 May; 78(20):1568-75. PubMed ID: 22517093
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The relationship between cerebrospinal fluid biomarkers and depression in elderly women.
    Gudmundsson P; Skoog I; Waern M; Blennow K; Pálsson S; Rosengren L; Gustafson D
    Am J Geriatr Psychiatry; 2007 Oct; 15(10):832-8. PubMed ID: 17911361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CSF amyloid beta42 and tau levels correlate with AIDS dementia complex.
    Brew BJ; Pemberton L; Blennow K; Wallin A; Hagberg L
    Neurology; 2005 Nov; 65(9):1490-2. PubMed ID: 16275845
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment.
    Hansson O; Zetterberg H; Buchhave P; Andreasson U; Londos E; Minthon L; Blennow K
    Dement Geriatr Cogn Disord; 2007; 23(5):316-20. PubMed ID: 17374949
    [TBL] [Abstract][Full Text] [Related]  

  • 35. White matter lesion severity is associated with reduced cognitive performances in patients with normal CSF Abeta42 levels.
    Stenset V; Hofoss D; Johnsen L; Skinningsrud A; Berstad AE; Negaard A; Reinvang I; Gjerstad L; Fladby T
    Acta Neurol Scand; 2008 Dec; 118(6):373-8. PubMed ID: 18510598
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.
    Fagan AM; Roe CM; Xiong C; Mintun MA; Morris JC; Holtzman DM
    Arch Neurol; 2007 Mar; 64(3):343-9. PubMed ID: 17210801
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study.
    Sluimer JD; Bouwman FH; Vrenken H; Blankenstein MA; Barkhof F; van der Flier WM; Scheltens P
    Neurobiol Aging; 2010 May; 31(5):758-64. PubMed ID: 18692273
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination of hippocampal volume and cerebrospinal fluid biomarkers improves predictive value in mild cognitive impairment.
    Eckerström C; Andreasson U; Olsson E; Rolstad S; Blennow K; Zetterberg H; Malmgren H; Edman A; Wallin A
    Dement Geriatr Cogn Disord; 2010; 29(4):294-300. PubMed ID: 20389071
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuropsychological and behavioural correlates of CSF biomarkers in dementia.
    Engelborghs S; Maertens K; Vloeberghs E; Aerts T; Somers N; Mariën P; De Deyn PP
    Neurochem Int; 2006 Mar; 48(4):286-95. PubMed ID: 16434124
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's disease.
    Wattmo C; Blennow K; Hansson O
    BMC Neurol; 2020 Jan; 20(1):10. PubMed ID: 31918679
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.